Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study of the Efficacy and Safety of IBI311, a Modified Anti-IGF-1R Antibody, in Patients With Steroid-resistant, Thyroid Associated Ophthalmopathy

NCT06269393 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT06269393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06269393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study of the Efficacy and Safety of IBI311, a Modified Anti-IGF-1R Antibody, in Patients With Steroid-resistant, Thyroid Associated Ophthalmopathy
Lead sponsor
Peking University People's Hospital
Phase
Phase 3
Overall status
Completed
Start date
January 1, 2024
Completion date
July 3, 2025
Enrollment
53 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid associated ophthalmopathy